Home > Insider Trading > Filing (0001567619-21-014361)

Filing Details

Accession Number:: 0001567619-21-014361
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-08-03 17:09:33
Reporting Period:: 2021-07-30

Accepted Time:: 2021-08-03 17:09:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372514	Eyegate Pharmaceuticals Inc	EYEG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 7Th Floor New York NY 10022	No	No	Yes	No
1633584	Ltd. Fund Master Capital Armistice	510 Madison Avenue, 7Th Floor New York NY 10022	No	No	Yes	No
1706140	Steven Boyd	510 Madison Avenue, 7Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-07-30	68,188	$2.69	977,775	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-08-02	192,775	$2.40	785,000	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.6145 to $2.7604, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.3595 to $2.5144, inclusive.